Sai Life Sciences has opened a new, dedicated facility (Unit VI) in Bidar, India, for the production of veterinary APIs. Located alongside its existing Unit IV, this expansion aims to meet growing demand for high-quality veterinary pharmaceuticals. The new facility incorporates advanced technologies and sustainable practices. Krishna Kanumuri, CEO, emphasized the company’s commitment to innovation and reliable solutions for animal well-being.
New Veterinary API Production
Sai Life Sciences has announced the opening of Unit VI in Bidar, India, a dedicated facility for veterinary API production. This facility, located with the company’s flagship API manufacturing site (Unit IV), focuses exclusively on producing APIs for veterinary applications. The announcement was made on September 18, 2025.
Facility Design and Objectives
The new facility is engineered to meet stringent safety, sustainability, and regulatory standards, ensuring the production of high-quality APIs for veterinary use. The company intends to provide efficient and scalable manufacturing solutions for leading global animal health companies. The investment aims to strengthen the ability to meet the increasing global need for high-quality veterinary pharmaceuticals.
Executive Commentary
Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, noted that the investment enhances the company’s ability to meet global demand and uphold high standards of innovation, efficiency, and sustainability. The company aims to support its partners in delivering reliable solutions for animal well-being.
Strategic Alignment
The investment in the new facility aligns with Sai Life Sciences’ strategic vision to enhance its offerings in niche, high-value segments within the pharmaceutical industry. The facility is equipped with advanced technologies and leverages robust supply chain management and safety practices.
Source: BSE
